GlassScriptPhysician profile
Nathaniel G Murphey
NPI 1720025307
$5,644.07
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,484 · 2020: $591 · 2021: $1,122 · 2022: $827 · 2023: $1,010 · 2024: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $828.04 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $743.26 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $701.12 | 2019-2024 | Breztri, Farxiga |
| Abbvie INC. | $606.10 | 2021-2024 | |
| Pfizer INC. | $512.25 | 2019-2024 | |
| Amgen INC. | $256.12 | 2019-2024 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $244.08 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.04 | 2020-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $215.93 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $155.10 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.54 | 2019-2024 | Trintellix |
| Abbott Laboratories | $144.37 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $99.01 | 2019-2023 | |
| Glaxosmithkline, LLC. | $89.71 | 2019-2023 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $79.05 | 2019-2023 | Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $76.58 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $67.70 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $59.33 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $56.58 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $43.90 | 2021 | |
| Amarin Pharma, INC. | $34.17 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $29.41 | 2019 | |
| Optinose US, INC. | $28.87 | 2021-2022 | |
| Antares Pharma, INC. | $27.18 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.67 | 2024 | |
| Astellas Pharma US INC | $18.25 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.08 | 2022 | |
| Alkermes, INC. | $16.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.83 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.72 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.07 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $15.03 | 2024 | Auvelity |
| Shield Therapeutics INC | $14.37 | 2022 | |
| Acadia Pharmaceuticals INC | $12.69 | 2019 | |
| Genentech USA, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Murphey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.